Effective November 29, 2022, Viatris completed the sale of
substantially all of its biosimilars portfolio (including related product trademarks)
to Biocon Biologics Limited and its subsidiaries (“Biocon”) and the relevant
marketing authorizations are in process of being transferred. Viatris Inc.
and its subsidiaries (“Viatris”) are not affiliates of Biocon but
are providing certain transition services to Biocon following the transaction
completion date, such as operating websites (including this site) relating to the biosimilars portfolio on Biocon’s behalf.
You are now leaving Ogiviri.com, a Viatris Inc. company website.
The website you are about to access is not owned or controlled by Viatris. Links to the other websites are provided as a convenience to users and the inclusion of any link does not imply the endorsement of the linked site by Viatris. Viatris accepts no responsibility for the content of any linked sites.
The information contained in this section of the site is intended for
US Healthcare professional only. Select “OK” if you are a US healthcare
professional.
Ogivri Prescribing Information. Mylan Inc. September 2019.
Rugo HS, Barve A, Waller CF, et al. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)–Positive metastatic breast cancer : a randomized clinical trial. JAMA. 2017;317:37-47.
Cardoso F, Bese N, Distelhorst SR, et al. Supportive care during treatment for breast cancer: resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. The Breast. 2013;22:593-605.